CGP 37849

CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects[1].

Product Specifications

CAS Number

[127910-31-0]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cgp-37849.html

Purity

99.0

Solubility

H2O : 20.91 mg/mL (ultrasonic)

Smiles

O=P(O)(O)C/C(C)=C/C(N)C(O)=O

Molecular Formula

C6H12NO5P

Molecular Weight

209.14

Precautions

H302, H315, H319, H335

References & Citations

[1]Fagg GE, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol. 1990 Apr;99 (4) :791-7.|[2]Schmutz M, et al. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342 (1) :61-6.|[3]Papp M, et al. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol. 1994 Sep 22;263 (1-2) :1-7.|[4]Przegaliński E, et al. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology. 2000 Jul 24;39 (10) :1858-64.